IFI35 Antibody (YA8137)

Cat. No.: HY-P88453: Data Sheet User Guide for Antibodies
FAQs
Technical Support

IFI35 Antibody (YA8137) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to IFI35.

For research use only. We do not sell to patients.

Size		Stock
50 μL		Get quote
100 μL		Get quote

* Please select Quantity before adding items.

WB: Western Blot;
IHC-P: Immunohistochemistry-Paraffin;
IHC-F: Immunohistochemistry-Frozen;
ICC/IF: Immunocytochemistry/Immunofluorescence;
IF-Tissue: Immunofluorescence-Tissue;
mIHC: Multiplex Immunohistochemical;
IP: Immunoprecipitation;
ChIP: Chromatin Immunoprecipitation;
FC: Flow Cytometry;
ELISA: Enzyme Linked Immunosorbent Assay

Product Detail
Background
Documentation

Description

IFI35 Antibody (YA8137) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to IFI35.

Host

Mouse

Clonality

Monoclonal

Molecular Weight

Predicted band size: 31.6 kDa

Species Reactivity

Human

SwissProt ID

P80217

Immunogen

Full length human recombinant protein of human IFI35produced in HEk293T cell

Application &
Dilution Ratio

Application	Dilution Ratio
IHC-P IHC-P: Immunohistochemistry-Paraffin	1:150-500
ICC/IF ICC/IF: Immunocytochemistry/Immunofluorescence	1:100-250
FC FC: Flow Cytometry	1:100

Sensitivity	Endogenous	Purity	Affinity purified
Conjugation	Non-conjugated	Modification	Unmodified
Isotype	IgG2a

Appearance

Liquid

Formulation

Spplied in PBS (pH 7.3) containing 1% BSA, 50% glycerol and 0.02% sodium azide.

Storage & Stability

Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.

Shipping

Shipping with blue ice.

Background

Function：Acts as a signaling pathway regulator involved in innate immune system response (PubMed:26342464, PubMed:29038465, PubMed:29350881). In response to interferon IFN-alpha, associates in a complex with signaling pathway regulator NMI to regulate immune response; the complex formation prevents proteasome-mediated degradation of IFI35 and correlates with IFI35 dephosphorylation (PubMed:10779520, PubMed:10950963). In complex with NMI, inhibits virus-triggered type I interferon/IFN-beta production (PubMed:26342464). In complex with NMI, negatively regulates nuclear factor NF-kappa-B signaling by inhibiting the nuclear translocation, activation and transcription of the NF-kappa-B subunit p65/RELA, resulting in the inhibition of endothelial cell proliferation, migration and re-endothelialization of injured arteries (PubMed:29350881). Beside its role as an intracellular signaling pathway regulator, also functions extracellularly as damage-associated molecular patterns (DAMPs) to promote inflammation when actively released by macrophage to the extracellular space during cell injury and pathogen invasion (PubMed:29038465). Macrophage-secreted IFI35 activates NF-kappa-B signaling in adjacent macrophages through Toll-like receptor 4/TLR4 activation, thereby inducing NF-kappa-B translocation from the cytoplasm into the nucleus which promotes the release of pro-inflammatory cytokines (PubMed:29038465)

Subcellular Localization：Cytoplasm,Nucleus,Secreted

Expression：
Tissue_Specificity: Expressed in a wide range of cell types, including fibroblasts, macrophages, and epithelial cells
Induction: Up-regulated by interferons IFN-alpha and IFN-gamma

Isoforms & Post-Translational Modification：P80217 has two isomers: P80217-1: 31546 Da (predicted); P80217-2: 31777 Da (predicted).
Phosphorylated

Subunit：Homodimer (PubMed:10950963, PubMed:8288566)

Synonyms

IFP35

Documentation

User Guide for Antibodies (1077 KB)